| Date Filed | Type | Description |
| 10/12/2023 |
10-Q
| Quarterly Report for the period ended August 31, 2023 |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/13/2023 |
10-Q
| Quarterly Report for the period ended May 31, 2023 |
| 07/13/2023 |
8-K
| Results of Operations and Financial Condition Interactive Data |
| 05/04/2023 |
4
| Silva Paul M (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Saltzman Edward C (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Reinsdorf Judith A (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Lacey David L. (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| Kunkel Lori Anne (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
4
| GREGORY JULIA P (Director) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $9.44, valued at
$236k
|
|
| 05/04/2023 |
8-K
| Quarterly results |
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/02/2023 |
4
| Ring Christine (General Counsel) has filed a Form 4 on Nurix Therapeutics, Inc.|
Txns:
| Sold 682 shares
@ $9.8763, valued at
$6.7k
Exercised 1,924 restricted stock units
@ $0 |
|
| 05/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/13/2023 |
10-Q
| Quarterly Report for the period ended February 28, 2023 |
| 04/13/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2023 |
8-K
| Other Events Interactive Data |
| 02/24/2023 |
SC 13G
| Deep Track Capital, LP reports a 5.8% stake in Nurix Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Third Rock Ventures III, L.P. reports a 0.4% stake in Nurix Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 10% stake in Nurix Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 6.9% stake in NURIX THERAPEUTICS INC |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| STATE STREET CORP reports a 5.3% stake in INITIAL FILING NURIX THERAPEUTICS INC |
| 02/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/09/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/09/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
|